本帖最后由 老马 于 2013-3-13 13:43 编辑 # n) B8 c9 b$ F1 |1 B9 b# t
0 B9 ?; N+ B! L. V2 h% E( [0 i健择(吉西他滨)+顺铂+阿瓦斯汀
0 m, i( m6 C4 j5 @; E Gemzar +Cisplatin + Avastin9 q0 n2 t. B# i0 C
http://annonc.oxfordjournals.org/content/21/9/1804.full3 G9 j/ [$ t. B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) K& q% k8 `4 K/ G b+ a; l8 zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) D) \1 X4 I2 m$ J# WResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. " q3 J5 F. F8 N- Q7 O0 f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 913)
8 N* n& o- i$ ~% R: @4 |! ~华为网盘附件:6 p+ _, E/ H' H; s- ?
【华为网盘】ava.JPG- h7 @& y4 y/ T% m2 A' J7 }6 x! L
|